Shopping Cart
Remove All
Your shopping cart is currently empty
YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $34 | In Stock | In Stock | |
| 5 mg | $55 | In Stock | In Stock | |
| 10 mg | $89 | In Stock | In Stock | |
| 25 mg | $189 | In Stock | In Stock | |
| 50 mg | $322 | In Stock | In Stock | |
| 100 mg | $563 | In Stock | In Stock | |
| 200 mg | $727 | - | In Stock | |
| 500 mg | $1,130 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $61 | In Stock | In Stock |
| Description | YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells carrying mtp53. |
| In vitro | YK-3-237 activates SIRT1 enzyme activities in vitro and deacetylation of both mtp53 in a SIRT1-dependent manner. |
| Synonyms | B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid |
| Molecular Weight | 372.18 |
| Formula | C19H21BO7 |
| Cas No. | 1215281-19-8 |
| Smiles | COc1ccc(\C=C\C(=O)c2cc(OC)c(OC)c(OC)c2)cc1B(O)O |
| Relative Density. | 1.26 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMF: 30 mg/mL (80.61 mM), Sonication is recommended. Ethanol: 10 mg/mL (26.87 mM), Sonication is recommended. DMSO: 30 mg/mL (80.61 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.37 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMF/DMSO
DMF/DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.